No reason not to expand them, except for: 1. Ha
Post# of 72440
1. Having sufficient funding to reach some sort of liquidity event for the studies/drugs already underway; and
2. Avoiding the issue in many people's minds of eventual resistence developing, to either B or K.
Remember, so many drugs have run into resistance in the past that a lot of people fixate on avoiding that, notwithstanding the less likely issue with our drugs.